Company / Capital Expenditures
NovoCure Ltd Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$26.6M
FY2025
5-year range
$21.4M / $42.9M
FY2021-FY2025
Trend
-37.8%
vs FY2024
Sector context
#95 of 145
Health Care
What the data says
At $27M, NovoCure Ltd's capital expenditures ranks #95 of 145 in the Health Care sector. Capital Expenditures has fluctuated over the past 10 years, ranging from $6M in FY2016 to $43M in FY2024.
Based on SEC 10-K filings.
$27M in FY2025 with a 5-year CAGR of +12.2%.
Remained stable around $27M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +7.7%
- 5-Year CAGR
- +12.2%
- 10-Year CAGR
- -
Sector benchmark
#95 of 145 in Health CareTop 66% of 145This company $26.6M Sector average $268.6M
▼
-90.1% below sector average
Key checks
Key Insights
- 5-year CAGR of +12.2%, indicating consistent growth.
- In FY2025, capital expenditures decreased 37.8% year-over-year.
- Ranks #95 out of 145 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $26.6M | -37.8% |
| FY2024 | $42.9M | +58.2% |
| FY2023 | $27.1M | +26.9% |
| FY2022 | $21.4M | -11.6% |
| FY2021 | $24.2M | +61.5% |
| FY2020 | $15.0M | +42.8% |
| FY2019 | $10.5M | +56.2% |
| FY2018 | $6.7M | -8.9% |
| FY2017 | $7.4M | +29.8% |
| FY2016 | $5.7M | +21.6% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026